It is well known that EGFR-mutated and ALK-translocated NSCLC treated with oncogene-driven targeted therapy has significantly better outcomes compared with standard platinum-based systemic therapy [25,26]. This evidence concerns the gene ALK and non-small cell lung carcinoma.